Lowering the alemtuzumab dose in reduced intensity conditioning allogeneic hematopoietic cell transplantation is associated with a favorable early intense natural killer cell recovery

Cytotherapy

Volumn 15, Issue 10, 2013, Pages 1237-1244

  Gärtner, Frank ^a   Hieke, Stefanie ^a   Finke, Jürgen ^a   Bertz, Hartmut ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Alemtuzumab; Hematopoietic cell transplantation; Natural killer cells; NK cell saving effect; Reduced intensity conditioning

Indexed keywords

ALEMTUZUMAB; CARMUSTINE; CYCLOSPORIN; FLUDARABINE; MELPHALAN; THIOTEPA;

ADULT; ADVANCED CANCER; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; OVERALL SURVIVAL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING;

ALEMTUZUMAB; HEMATOPOIETIC CELL TRANSPLANTATION; NATURAL KILLER CELLS; NK CELL SAVING EFFECT; REDUCED INTENSITY CONDITIONING;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD; ANTIGENS, NEOPLASM; CELL SURVIVAL; CLINICAL PROTOCOLS; DRUG DOSAGE CALCULATIONS; FEMALE; GLYCOPROTEINS; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSTOPERATIVE COMPLICATIONS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84883230150     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2013.05.016     Document Type: Article

References (29)

1. Alousi A., de Lima M. Reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. Clin Adv Hematol Oncol 2007, 5:560-570.
2. Pollack S.M., O'Connor T.P., Hashash J., Tabbara I.A. Nonmyeloablative and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation: a clinical review. Am J Clin Oncol 2009, 32:618-628.
3. Hale G., Waldmann H. CAMPATH-1 monoclonal antibodies in bone marrow transplantation. JHematother 1994, 3:15-31.
4. Rodig S.J., Abramson J.S., Pinkus G.S., Treon S.P., Dorfman D.M., Dong H.Y., et al. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res 2006, 12:7174-7179.
5. Xia M.Q., Hale G., Waldmann H. Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen. Mol Immunol 1993, 30:1089-1096.
6. Nückel H., Frey U.H., Röth A., Dührsen U., Siffert W. Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity. Eur J Pharmacol 2005, 514:217-224.
7. Gribben J.G., Hallek M. Rediscovering alemtuzumab: current and emerging therapeutic roles. Br J Haematol 2009, 144:818-831.
8. Hale G., Bright S., Chumbley G., Hoang T., Metcalf D., Munro A.J., et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood 1983, 62:873-882.
9. Waldmann H., Polliak A., Hale G., Or R., Cividalli G., Weiss L., et al. Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet 1984, 2:483-486.
10. Kottaridis P.D., Milligan D.W., Chopra R., Chakraverty R.K., Chakrabarti S., Robinson S., et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000, 96:2419-2425.
11. Wäsch R., Reisser S., Hahn J., Bertz H., Engelhardt M., Kunzmann R., et al. Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation. Bone Marrow Transplant 2000, 26:243-250.
12. Marks R., Potthoff K., Hahn J., Ihorst G., Bertz H., Spyridonidis A., et al. Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies. Blood 2008, 112:415-425.
13. Bertz H., Spyridonidis A., Wäsch R., Grüllich C., Egger M., Finke J. Anovel GVHD-prophylaxis with low-dose alemtuzumab in allogeneic sibling or unrelated donor hematopoietic cell transplantation: the feasibility of deescalation. Biol Blood Marrow Transplant 2009, 15:1563-1570.
14. Chakraverty R., Orti G., Roughton M., Shen J., Fielding A., Kottaridis P., et al. Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD and immune reconstitution. Blood 2010, 116:3080-3088.
15. Cox D.R. Regression models and life-tables. JR Stat Soc Ser B Methodol 1972, 34:187-220.
16. Dunbar E.M., Buzzeo M.P., Levine J.B., Schold J.D., Meier-Kriesche H., Reddy V. The relationship between circulating natural killer cells after reduced intensity conditioning hematopoietic stem cell transplantation and relapse-free survival and graft-versus-host disease. Haematologica 2008, 93:1852-1858.
17. Comans-Bitter W.M., de Groot R., van den Beemd R., Neijens H.J., Hop W.C., Groeneveld K., et al. Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations. JPediatr 1997, 130:388-393.
18. Drach D., Zhao S., Drach J., Mahadevia R., Gattringer C., Huber H., et al. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 1992, 80:2729-2734.
19. Chaudhary P.M., Mechetner E.B., Roninson I.B. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992, 80:2735-2739.
20. Dulphy N., Haas P., Busson M., Belhadj S., Peffault de Latour R., Robin M., et al. An unusual CD56(bright) CD16(low) NK cell subset dominates the early posttransplant period following HLA-matched hematopoietic stem cell transplantation. JImmunol 2008, 181:2227-2237.
21. Hernández-Campo P.M., Almeida J., Sánchez M.L., Malvezzi M., Orfao A. Normal patterns of expression of glycosylphosphatidylinositol-anchored proteins on different subsets of peripheral blood cells: a frame of reference for the diagnosis of paroxysmal nocturnal hemoglobinuria. Cytometry B Clin Cytom 2006, 70:71-81.
22. Cooper M.A., Fehniger T.A., Turner S.C., Chen K.S., Ghaheri B.A., Ghayur T., et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 2001, 97:3146-3151.
23. Smyth M.J., Cretney E., Kelly J.M., Westwood J.A., Street S.E., Yagita H., et al. Activation of NK cell cytotoxicity. Mol Immunol 2005, 42:501-510.
24. Di Santo J.P. Natural killer cells: diversity in search of a niche. Nat Immunol 2008, 9:473-475.
25. Lanier L.L. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008, 9:495-502.
26. Ruggeri L., Capanni M., Urbani E., Perruccio K., Shlomchik W.D., Tosti A., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
27. Kärre K., Ljunggren H.G., Piontek G., Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986, 319:675-678.
28. Lodoen M.B., Lanier L.L. Natural killer cells as an initial defense against pathogens. Curr Opin Immunol 2006, 18:391-398.
29. Gratwohl A., Stern M., Brand R., Apperley J., Baldomero H., de Witte T., et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer 2009, 115:4715-4726.